clinical trial · NCT05783622
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Non-Small Cell Lung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the Head and NeckColorectal CarcinomaSmall Cell Lung CancerPancreatic Ductal AdenocarcinomaTriple-negative Breast CancerJANX008
brief summary
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.
started
Apr 19, 2023
primary completion
Jan 1, 2026
completion
Oct 1, 2027
last updated
Oct 14, 2025
official title
An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol